V. S. Bashnyak
Research Subjects
V. S. Bashnyak has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Oksana Mikhailovna Drapkina
National Medical Research Center for Therapy and Preventive Medicine, Ministry of Health of Russia
5 shared publications - Svetlana A. Berns
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
4 shared publications - Alexander Yuryevich Gorshkov
National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
3 shared publications - Anna A. Ivanova
National Medical Research Center for Therapy and Preventive Medicine
3 shared publications - L. N. Ryzhakova
National Medical Research Center for Therapy and Preventive Medicine
3 shared publications - K. S. Krupichka
National Medical Research Center for Therapy and Preventive Medicine
2 shared publications
Latest Publications
- Open Access
- 1 August 2024
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 23 (8) , 4050
Anomalous origin of left coronary artery. RAC-sign. A case report
Anomalous coronary origin is a rarely diagnosed condition, the first manifestation of which may be sudden cardiac death. Diagnosis of this pathology, as well as other cardiac and coronary anomalies, is based on imaging diagnostic methods. Transthoracic echocardiography is the most accessible screening method to describe the retroaortic anomalous coronary (RAC) sign. However, due to the low detection rate of this condition and the suboptimal sensitivity of echocardiography, anomalous aortic origin often remains undiagnosed. This article presents the diagnosis of an anomalous origin of the left coronary artery through echocardiography and computed tomography in an elderly patient who had previously been observed for a long time for other cardiovascular diseases. With this case report, we want to emphasize the importance of awareness about congenital coronary artery pathology for the timely routing of patients and providing proper care.
- 1 August 2024
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 23 (8) , 4050
Open AccessAnomalous origin of left coronary artery. RAC-sign. A case report
Anomalous coronary origin is a rarely diagnosed condition, the first manifestation of which may be sudden cardiac death. Diagnosis of this pathology, as well as other cardiac and coronary anomalies, is based on imaging diagnostic methods. Transthoracic echocardiography is the most accessible screening method to describe the retroaortic anomalous coronary (RAC) sign. However, due to the low detection rate of this condition and the suboptimal sensitivity of echocardiography, anomalous aortic origin often remains undiagnosed. This article presents the diagnosis of an anomalous origin of the left coronary artery through echocardiography and computed tomography in an elderly patient who had previously been observed for a long time for other cardiovascular diseases. With this case report, we want to emphasize the importance of awareness about congenital coronary artery pathology for the timely routing of patients and providing proper care.
- Open Access
- 30 April 2024
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 64 (4) , 72-78
Features of the Course of Arterial Hypertension in the Era of the COVID-19 Pandemic: Common Pathogenetic Links Between Hypertension and SARS-CoV-2
The aim of this review was to present the mechanism of infection with severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) and its possible effect on the course of arterial hypertension. Another aim was to evaluate the relationship of the renin-angiotensin-aldosterone system with the pathogenetic stages of infection caused by SARS-CoV-2 virus.
- 30 April 2024
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 64 (4) , 72-78
Open AccessFeatures of the Course of Arterial Hypertension in the Era of the COVID-19 Pandemic: Common Pathogenetic Links Between Hypertension and SARS-CoV-2
The aim of this review was to present the mechanism of infection with severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) and its possible effect on the course of arterial hypertension. Another aim was to evaluate the relationship of the renin-angiotensin-aldosterone system with the pathogenetic stages of infection caused by SARS-CoV-2 virus.
- Open Access
- 14 June 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (7S) , 3627
"Suffocating from the unknown". Case report
Pulmonary hypertension is an extremely rare disease that threatens the life of patients. It is necessary to clearly understand the diagnosis criteria and evaluate the effectiveness of specific therapy. In a case report, an algorithm is described step by step that helps to come to a rare and interesting diagnosis.
- 14 June 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (7S) , 3627
Open Access"Suffocating from the unknown". Case report
Pulmonary hypertension is an extremely rare disease that threatens the life of patients. It is necessary to clearly understand the diagnosis criteria and evaluate the effectiveness of specific therapy. In a case report, an algorithm is described step by step that helps to come to a rare and interesting diagnosis.
- Open Access
- 8 July 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (6) , 3295
Association of humoral immunity status and thrombodynamics after vaccination with Gam-COVID-Vac and CoviVac
The ongoing pandemic of coronavirus disease 2019 makes it important to study the immunogenicity, the duration of immune response, and the safety of existing vaccines.Aim. As part of a prospective observational study, to assess associations between levels of anti-Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) S protein IgG antibodies and thrombodynamics parameters in individuals vaccinated with Gam-COVID-Vac and CoviVac vaccines.Material and methods. The study included 137 people who completed the first 3 visits: 30 people received the Gam-COVID-Vac, 107 people — CoviVac. The study participants underwent venous blood sampling before the introduction of the 1st and 2nd vaccine doses, as well as 42 days after the administration of 1st dose in order to quantify the level of IgG antibodies. At each visit, plasma hemostasis parameters were analyzed using a thrombodynamics test.Results. During the follow-up period, there was a clear increase in the level of anti-SARS-CoV-2 S protein IgG antibodies in both groups. At the same time, this increase over time was significantly greater in Gam-COVID-Vac group. There was no correlation detected between thrombodynamics test results and the levels of anti-SARS-CoV-2 S protein IgG antibodies.Conclusion. The data obtained demonstrate the ability of both vaccines to stimulate the production of anti-SARS-CoV-2 antibodies. However, immune response to Gam-COVID-Vac is much higher. The lack of correlation between thrombodynamics and the level of specific antibodies suggests that vaccination for COVID-19 with Gam-COVIDVac and CoviVac does not cause changes in plasma hemostasis and does not increase the risk of thrombosis.
- 8 July 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (6) , 3295
Open AccessAssociation of humoral immunity status and thrombodynamics after vaccination with Gam-COVID-Vac and CoviVac
The ongoing pandemic of coronavirus disease 2019 makes it important to study the immunogenicity, the duration of immune response, and the safety of existing vaccines.Aim. As part of a prospective observational study, to assess associations between levels of anti-Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) S protein IgG antibodies and thrombodynamics parameters in individuals vaccinated with Gam-COVID-Vac and CoviVac vaccines.Material and methods. The study included 137 people who completed the first 3 visits: 30 people received the Gam-COVID-Vac, 107 people — CoviVac. The study participants underwent venous blood sampling before the introduction of the 1st and 2nd vaccine doses, as well as 42 days after the administration of 1st dose in order to quantify the level of IgG antibodies. At each visit, plasma hemostasis parameters were analyzed using a thrombodynamics test.Results. During the follow-up period, there was a clear increase in the level of anti-SARS-CoV-2 S protein IgG antibodies in both groups. At the same time, this increase over time was significantly greater in Gam-COVID-Vac group. There was no correlation detected between thrombodynamics test results and the levels of anti-SARS-CoV-2 S protein IgG antibodies.Conclusion. The data obtained demonstrate the ability of both vaccines to stimulate the production of anti-SARS-CoV-2 antibodies. However, immune response to Gam-COVID-Vac is much higher. The lack of correlation between thrombodynamics and the level of specific antibodies suggests that vaccination for COVID-19 with Gam-COVIDVac and CoviVac does not cause changes in plasma hemostasis and does not increase the risk of thrombosis.
- Open Access
- 26 June 2022
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 11 (2) , 196-203
Booster vaccination against SARS-CoV-2: current challenges and solutions
Highlights. Nowadays the only way to prevent a new coronavirus infection is vaccination. Overcoming such problems as a gradual decrease in the effectiveness of post-vaccination immunity and the emergence of new strains of SARS-CoV-2 is possible due to booster vaccination. The review highlights the current data on the effectiveness and immunogenicity of various booster vaccination regimens and prospects for studying this issue in the Russian Federation. The COVID-19 pandemic is going on, which makes it crucial to prevent the spread of coronavirus disease. Vaccination is the only way of specific prevention of COVID-19. The SARS-CoV-2 virus is continuously evolving and new variants appear. Moreover, the effectiveness of protective immunity after vaccination tends to decrease over several months. Booster vaccination may be the solution to these problems. The booster is an extra vaccination that helps to reactivate the immunity against COVID-19. Booster doses can be homologous (the same as the primary vaccine) and heterologous (different from the primary vaccine). It is of current interest to study heterologous vaccination as the injection of different vaccines may result in a more intense immune response. Furthermore, the same vaccine may not be available at the time of booster vaccination. This review is aimed at summarizing the key research findings in the field of booster vaccination against COVID-19.
- 26 June 2022
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 11 (2) , 196-203
Open AccessBooster vaccination against SARS-CoV-2: current challenges and solutions
Highlights. Nowadays the only way to prevent a new coronavirus infection is vaccination. Overcoming such problems as a gradual decrease in the effectiveness of post-vaccination immunity and the emergence of new strains of SARS-CoV-2 is possible due to booster vaccination. The review highlights the current data on the effectiveness and immunogenicity of various booster vaccination regimens and prospects for studying this issue in the Russian Federation. The COVID-19 pandemic is going on, which makes it crucial to prevent the spread of coronavirus disease. Vaccination is the only way of specific prevention of COVID-19. The SARS-CoV-2 virus is continuously evolving and new variants appear. Moreover, the effectiveness of protective immunity after vaccination tends to decrease over several months. Booster vaccination may be the solution to these problems. The booster is an extra vaccination that helps to reactivate the immunity against COVID-19. Booster doses can be homologous (the same as the primary vaccine) and heterologous (different from the primary vaccine). It is of current interest to study heterologous vaccination as the injection of different vaccines may result in a more intense immune response. Furthermore, the same vaccine may not be available at the time of booster vaccination. This review is aimed at summarizing the key research findings in the field of booster vaccination against COVID-19.
- Open Access
- 12 January 2022
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 28 (1) , 96-102
Hypertension as a mask of ANCA-associated glomerulonephritis
Glomerulonephritis associated with antineutrophil cytoplasmic antibodies (ANCA) is one of the causes of renal parenchymal disease, which can lead to secondary hypertension (HTN). Clinical course of HTN in this case is usually mild, however, high blood pressure can become the only reason to refer to a primary care physician. We report a case of a 45-year old woman with renal parenchymal disease due to ANCA-glomerulonephritis and secondary HTN. HTN was the only clinical manifestation of the disease led to the hospital admission. With this clinical case we emphasize that primary care physicians should always attempt to identify secondary causes of HTN.
- 12 January 2022
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 28 (1) , 96-102
Open AccessHypertension as a mask of ANCA-associated glomerulonephritis
Glomerulonephritis associated with antineutrophil cytoplasmic antibodies (ANCA) is one of the causes of renal parenchymal disease, which can lead to secondary hypertension (HTN). Clinical course of HTN in this case is usually mild, however, high blood pressure can become the only reason to refer to a primary care physician. We report a case of a 45-year old woman with renal parenchymal disease due to ANCA-glomerulonephritis and secondary HTN. HTN was the only clinical manifestation of the disease led to the hospital admission. With this clinical case we emphasize that primary care physicians should always attempt to identify secondary causes of HTN.
- Open Access
- 8 January 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 20 (8) , 3124
Long-term dynamics of the levels of anti-SARS-CoV-2 S-protein IgG antibodies in vaccinated individuals
In the context of the ongoing coronavirus disease 2019 (COVID-19) pandemic, it is extremely important to study immunogenicity and immune response duration in different vaccines.Aim. As part of a prospective observational study, to study the levels of anti-SARS-CoV-2 S-protein IgG antibodies in individuals vaccinated with the Gam-COVID-Vac and CoviVac vaccines.Material and methods. The data of 93 people who completed the first 3 visits were analyzed, 23 of whom were vaccinated with the Gam-COVID-Vac vaccine and 70 people — with the CoviVac vaccine. We collected blood before the injection of vaccine doses I and II, as well as 42 days after the injection of dose I in order to quantitatively determine IgG levels. The level of anti-SARS-CoV-2 S-protein IgG antibodies was determined using the SARS-CoV-2 IgG ELISA-BEST reagent kit on the InfiniteF50 TECAN system.Results. A significant increase in anti-SARS-CoV-2 S-protein IgG antibodies was observed in those vaccinated with Gam-COVID-Vac. In the group of CoviVac vaccine, an increase in the level anti-SARS-CoV-2 S-protein IgG antibodies in absolute values was recorded, however, this increase did not reach statistical significance.Conclusion. The data obtained show that the level of anti-SARS-CoV-2 S-protein antibodies 42 days after Gam-COVID-Vac vaccination is significantly higher than after CoviVac vaccination. However, an increase in the level of IgG in both groups indicates the ability of both vaccines to stimulate the production of anti-SARS-CoV antibodies.
- 8 January 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 20 (8) , 3124
Open AccessLong-term dynamics of the levels of anti-SARS-CoV-2 S-protein IgG antibodies in vaccinated individuals
In the context of the ongoing coronavirus disease 2019 (COVID-19) pandemic, it is extremely important to study immunogenicity and immune response duration in different vaccines.Aim. As part of a prospective observational study, to study the levels of anti-SARS-CoV-2 S-protein IgG antibodies in individuals vaccinated with the Gam-COVID-Vac and CoviVac vaccines.Material and methods. The data of 93 people who completed the first 3 visits were analyzed, 23 of whom were vaccinated with the Gam-COVID-Vac vaccine and 70 people — with the CoviVac vaccine. We collected blood before the injection of vaccine doses I and II, as well as 42 days after the injection of dose I in order to quantitatively determine IgG levels. The level of anti-SARS-CoV-2 S-protein IgG antibodies was determined using the SARS-CoV-2 IgG ELISA-BEST reagent kit on the InfiniteF50 TECAN system.Results. A significant increase in anti-SARS-CoV-2 S-protein IgG antibodies was observed in those vaccinated with Gam-COVID-Vac. In the group of CoviVac vaccine, an increase in the level anti-SARS-CoV-2 S-protein IgG antibodies in absolute values was recorded, however, this increase did not reach statistical significance.Conclusion. The data obtained show that the level of anti-SARS-CoV-2 S-protein antibodies 42 days after Gam-COVID-Vac vaccination is significantly higher than after CoviVac vaccination. However, an increase in the level of IgG in both groups indicates the ability of both vaccines to stimulate the production of anti-SARS-CoV antibodies.